Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Establishment Labs Holdings Inc. (NASDAQ: ESTA) provides access to the company’s U.S. regulatory disclosures as a global medical device issuer focused on breast aesthetics and reconstruction. Through these documents, investors can review how Establishment Labs reports its financial condition, operating results, and key corporate agreements.
Core filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company details revenue from its portfolio of breast health, breast aesthetics, and breast reconstruction products, as well as expenses, liquidity, and risk factors. These reports also describe its manufacturing operations in Costa Rica, quality system compliance under ISO 13485:2016 and FDA 21 CFR 820, and its intellectual property position, including patent applications and clinical evidence supporting its devices.
Current reports on Form 8-K are particularly relevant for tracking material events at Establishment Labs. Recent 8-K filings have covered earnings announcements for specific quarters and an amendment to the company’s credit agreement with Oaktree Fund Administration, LLC, including the availability of additional term loan tranches and related liquidity requirements. Such filings help clarify changes in capital structure, borrowing capacity, and other significant developments.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the content of complex filings. Users can quickly understand the implications of new 10-K and 10-Q reports, 8-K current events, and other submissions without reading every page. The platform also surfaces insider transaction disclosures on Form 4, allowing users to monitor equity transactions by Establishment Labs’ directors and officers as reported to the SEC.
Nantahala Capital Management and its principals reported a mid‑single‑digit stake in Establishment Labs Holdings Inc. As of December 31, 2025, Nantahala and Wilmot B. Harkey each may be deemed to beneficially own 987,689 common shares, or about 3.40% of outstanding shares, while Daniel Mack is reported at 3.50%, including 28,218 shares he controls solely. The securities are described as held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Brown Advisory Inc and related entities reported beneficial ownership of 2,038,652 Establishment Labs Holdings Inc. common shares, representing 7.02% of the class as of 12/31/2025.
Most voting power sits with Brown Advisory Inc and Brown Advisory LLC, while dispositive power is largely shared across subsidiaries. The shares are beneficially owned by investment companies and other managed accounts of Brown Advisory’s subsidiaries. The group certifies the holdings are in the ordinary course of business and not intended to change or influence control of Establishment Labs.
Establishment Labs Holdings Inc. filed a Form 8-K to share that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026. The company is furnishing, rather than filing, the investor presentation as Exhibit 99.1, meaning it is not subject to certain liability provisions that apply to filed information.
The report highlights that the materials may contain forward-looking statements and preliminary financial data prepared by management. The company notes that its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, or provided any assurance on this preliminary financial information, so it should not be relied on as a substitute for full GAAP financial statements.
Establishment Labs Holdings Inc. reported that it has issued a press release with preliminary, unaudited financial information for the quarter and full year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report.
The company emphasizes that these consolidated preliminary estimates are forward-looking statements, may differ materially from actual results, and are not a substitute for full financial statements prepared under U.S. GAAP. Its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, compiled, or performed any procedures on this preliminary information and does not provide any assurance on it.
Establishment Labs Holdings Inc. director Juan Jose Chacon Quiros reported new equity awards. On August 3, 2025, he received 10,285 common shares at a price of $0, increasing his directly held common shares to 224,433. These stock units were granted under the company’s 2018 Equity Incentive Plan and are tied to a post-employment agreement signed on that date and a consulting agreement effective June 1, 2025.
He was also granted a stock option for 14,906 common shares with an exercise price of $36.46, fully unexercised after the transaction. Both the stock units and the option vest in four equal annual installments starting on June 1, 2026, as long as he continues as a service provider. Separately, 1,078,264 common shares are held indirectly by Sariel Group Ltd, an entity where he has voting and dispositive power but for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Establishment Labs Holdings Inc. (ESTA) reported an insider transaction on a joint Form 4 by affiliates of JW Asset Management. On 11/10/2025, the group reported an open‑market sale of 11,000 common shares at a price of $67.07 per share. Following the transaction, the group reported 3,061,694 shares beneficially owned, held indirectly.
Footnotes state the sale comprised 8,205 shares by JW Partners, LP and 2,795 shares by JW Opportunities Fund, LLC, with standard disclaimers regarding indirect pecuniary interest.
Establishment Labs (ESTA) reported an insider transaction on a Form 4 by JW Asset Management, LLC and affiliated reporting persons. On 11/07/2025, the group sold 2,500 common shares in an open-market transaction at $65.09 per share (transaction code S). Following the sale, the reporting persons beneficially owned 3,072,694 shares, held indirectly.
Per the footnotes, the 2,500 shares reflect sales by two affiliated funds: 1,865 shares by JW Partners, LP and 635 shares by JW Opportunities Fund, LLC. The filing indicates the structure of control and advisory roles among JW Asset Management, LLC, JW GP, LLC, and Jason G. Wild, with beneficial ownership disclaimed except to the extent of any indirect pecuniary interest.
Establishment Labs Holdings (ESTA) reported an insider transaction on a Form 4 involving multiple reporting persons affiliated with JW Asset Management. On 11/06/2025, the group sold 7,591 Common Shares at a price of $65 per share, coded “S” for sale. Following the transaction, 3,075,194 shares were reported as beneficially owned in aggregate with indirect ownership noted.
Footnotes state the sale comprised 5,662 shares by JW Partners, LP and 1,929 shares by JW Opportunities Fund, LLC. The filing lists JW Asset Management, LLC, JW Partners, LP, JW Opportunities Fund, LLC, JW GP, LLC, and Jason G. Wild as reporting persons, with customary beneficial ownership disclaimers. The form indicates it was filed by more than one reporting person.
Establishment Labs (ESTA) reported Q3 2025 results. Revenue reached $53.8 million, up from $40.2 million a year ago, with gross profit of $37.7 million. Operating loss narrowed to $4.0 million and net loss was $11.1 million, or $0.38 per share.
North America contributed $11.9 million in Q3 revenue versus $0.3 million in the prior year period. For the first nine months, revenue was $146.5 million and net loss was $48.4 million.
Cash and cash equivalents were $70.6 million at quarter-end. Year-to-date net cash used in operating activities was $50.7 million. Note payable, net, increased to $246.5 million from $219.6 million at year-end 2024, and shareholders’ equity declined to $16.4 million from $53.1 million. The company had 29,057,868 common shares outstanding as of November 6, 2025.
Establishment Labs Holdings Inc. (ESTA) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company made these results available through a press release attached as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not filed under the Exchange Act.
FAQ
What is the current stock price of Establishment Labs Hldgs (ESTA)?
What is the market cap of Establishment Labs Hldgs (ESTA)?
